|
1
|
Guieu R, Fromonot J, Mottola G, Maille B, Marlinge M, Groppelli A, Conte S, Bechah Y, Lalevee N, Michelet P, Hamdan M, Brignole M, Deharo JC. Adenosinergic System and Neuroendocrine Syncope: What Is the Link? Cells 2023; 12:2027. [PMID: 37626837 PMCID: PMC10453095 DOI: 10.3390/cells12162027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 08/02/2023] [Accepted: 08/03/2023] [Indexed: 08/27/2023] Open
Abstract
Although very common, the precise mechanisms that explain the symptomatology of neuroendocrine syncope (NES) remain poorly understood. This disease, which can be very incapacitating, manifests itself as a drop in blood pressure secondary to vasodilation and/or extreme slowing of heart rate. As studies continue, the involvement of the adenosinergic system is becoming increasingly evident. Adenosine, which is an ATP derivative, may be involved in a large number of cases. Adenosine acts on G protein-coupled receptors with seven transmembrane domains. A1 and A2A adenosine receptor dysfunction seem to be particularly implicated since the activation leads to severe bradycardia or vasodilation, respectively, two cardinal symptoms of NES. This mini-review aims to shed light on the links between dysfunction of the adenosinergic system and NHS. In particular, signal transduction pathways through the modulation of cAMP production and ion channels in relation to effects on the cardiovascular system are addressed. A better understanding of these mechanisms could guide the pharmacological development of new therapeutic approaches.
Collapse
Affiliation(s)
- Régis Guieu
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Laboratory of Biochemistry, AP-HM, 13005 Marseille, France;
| | - Julien Fromonot
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Laboratory of Biochemistry, AP-HM, 13005 Marseille, France;
| | - Giovanna Mottola
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Laboratory of Biochemistry, AP-HM, 13005 Marseille, France;
| | - Baptiste Maille
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Department of Cardiology, Syncope Unit, Timone Hospital, 13005 Marseille, France
| | - Marion Marlinge
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Laboratory of Biochemistry, AP-HM, 13005 Marseille, France;
| | - Antonella Groppelli
- IRCCS Istituto Auxologico Italiano, Department of Cardiology, San Luca Hospital, Piazzale Brescia 20, 20149 Milan, Italy; (A.G.); (M.B.)
| | - Samantha Conte
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
| | - Yassina Bechah
- Laboratory of Biochemistry, AP-HM, 13005 Marseille, France;
| | - Nathalie Lalevee
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
| | - Pierre Michelet
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Department of Anesthesia and Reanimation, Hopital Conception, 13005 Marseille, France
| | - Mohamed Hamdan
- Department of Medicine, Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA;
| | - Michele Brignole
- IRCCS Istituto Auxologico Italiano, Department of Cardiology, San Luca Hospital, Piazzale Brescia 20, 20149 Milan, Italy; (A.G.); (M.B.)
| | - Jean Claude Deharo
- Centre for Cardiovascular Research and Nutrition (C2VN), INSERM, INRAE, AMU, 13005 Marseille, France; (J.F.); (B.M.); (M.M.); (S.C.); (N.L.); (P.M.); (J.C.D.)
- Department of Cardiology, Syncope Unit, Timone Hospital, 13005 Marseille, France
| |
Collapse
|
|
2
|
Adenosine and Adenosine Receptors: Advances in Atrial Fibrillation. Biomedicines 2022; 10:biomedicines10112963. [PMID: 36428533 PMCID: PMC9687155 DOI: 10.3390/biomedicines10112963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 11/07/2022] [Accepted: 11/14/2022] [Indexed: 11/19/2022] Open
Abstract
Atrial fibrillation (AF) is the most common arrhythmia in the world. Because the key to developing innovative therapies that limit the onset and the progression of AF is to fully understand the underlying molecular mechanisms of AF, the aim of the present narrative review is to report the most recent advances in the potential role of the adenosinergic system in the pathophysiology of AF. After a comprehensive approach describing adenosinergic system signaling and the mechanisms of the initiation and maintenance of AF, we address the interactions of the adenosinergic system's signaling with AF. Indeed, adenosine release can activate four G-coupled membrane receptors, named A1, A2A, A2B and A3. Activation of the A2A receptors can promote the occurrence of delayed depolarization, while activation of the A1 receptors can shorten the action potential's duration and induce the resting membrane's potential hyperpolarization, which promote pulmonary vein firing, stabilize the AF rotors and allow for functional reentry. Moreover, the A2B receptors have been associated with atrial fibrosis homeostasis. Finally, the adenosinergic system can modulate the autonomous nervous system and is associated with AF risk factors. A question remains regarding adenosine release and the adenosine receptors' activation and whether this would be a cause or consequence of AF.
Collapse
|